Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BridgeBio Pharma (BBIO) Cash & Equivalents (2019 - 2025)

Historic Cash & Equivalents for BridgeBio Pharma (BBIO) over the last 7 years, with Q3 2025 value amounting to $643.0 million.

  • BridgeBio Pharma's Cash & Equivalents rose 14141.68% to $643.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $643.0 million, marking a year-over-year increase of 14141.68%. This contributed to the annual value of $681.1 million for FY2024, which is 8117.52% up from last year.
  • Per BridgeBio Pharma's latest filing, its Cash & Equivalents stood at $643.0 million for Q3 2025, which was up 14141.68% from $749.0 million recorded in Q2 2025.
  • In the past 5 years, BridgeBio Pharma's Cash & Equivalents registered a high of $749.0 million during Q2 2025, and its lowest value of $180.3 million during Q3 2021.
  • Its 5-year average for Cash & Equivalents is $446.3 million, with a median of $408.0 million in 2024.
  • Its Cash & Equivalents has fluctuated over the past 5 years, first plummeted by 5085.47% in 2021, then skyrocketed by 16794.73% in 2022.
  • Quarter analysis of 5 years shows BridgeBio Pharma's Cash & Equivalents stood at $393.8 million in 2021, then dropped by 4.34% to $376.7 million in 2022, then dropped by 0.2% to $375.9 million in 2023, then skyrocketed by 81.18% to $681.1 million in 2024, then fell by 5.6% to $643.0 million in 2025.
  • Its last three reported values are $643.0 million in Q3 2025, $749.0 million for Q2 2025, and $540.6 million during Q1 2025.